Latest Capital Raise News

Aquirian Limited reported a 12.6% revenue increase to $26.07 million for FY25 but posted a $3.41 million statutory loss amid ramp-up costs and impairments. The company is advancing its Energetics and Technology divisions, including the Wubin Emulsion Facility and Collar Keeper® System.

Qoria Limited reported a robust FY2025 with 25% growth in annual recurring revenue and a 684% jump in EBITDA, underscoring its expanding leadership in global K12 safety and wellbeing platforms.

Ai-Media Technologies reported a 2.1% revenue decline to $64.86 million in FY25, driven by a strategic shift to technology sales and a 25% drop in services revenue. Despite a higher net loss, underlying EBITDA rose 11%, reflecting progress in its SaaS transformation and global expansion.

RocketDNA Ltd reported a slight revenue decline and increased losses in H1 2025 but marked significant progress in drone technology deployments and operational certifications.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Midas Minerals has secured a crucial licence transfer for its Otavi Copper Project acquisition in Namibia, moving closer to drilling plans slated for late 2025. The company now awaits final regulatory approval and capital raising to complete the deal.

Macquarie Technology Group reported modest revenue and profit growth for FY25, underpinned by a new $450 million undrawn debt facility aimed at expanding its data centre portfolio. The company’s strategic investments include the on-time construction of IC3 SuperWest and a $240 million option to acquire land for a new Sydney campus.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Gryphon Capital Income Trust (ASX, GCI) reported a robust fiscal 2025 with a 41.65% jump in revenue and a substantial capital raise to expand its RMBS/ABS portfolio. The Trust’s net assets topped $1 billion, reflecting strong investor confidence and strategic growth.

Flight Centre Travel Group has launched a A$450 million convertible notes offering due 2032, aiming to repurchase up to A$325 million of existing notes and support its growth ambitions with extended debt maturity.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.